<DOC>
	<DOCNO>NCT02016911</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacokinetics ( exposure trial drug body ) , safety tolerability oral semaglutide ( NNC0113-0217 ) subject mild , moderate severe degree hepatic impairment compare subject normal hepatic function .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Oral Semaglutide Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subject normal hepatic function hepatic impairment ( mild , moderate severe ) Body mass index ( BMI ) 18.540.0 kg/m^2 ( inclusive ) Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method History Crohn 's disease , ulcerative colitis , inflammatory bowel disease Uncontrolled hypertension ( define systolic blood pressure equal 180 mmHg and/or diastolic blood pressure equal 100 mmHg ) Any donation blood plasma excess 400 mL within 3 month precede screen History significant drug abuse , positive drug test screen visit ( Visit 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>